VAFP
REGN icon

Vahanian & Associates Financial Planning’s Regeneron Pharmaceuticals REGN Stock Holding History

Vahanian & Associates Financial Planning’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-528
Closed -$369K – 59
2022
Q1 		$369K Sell
528
-526
-50% -$333K 0.85% 32
2021
Q4 		$666K Buy
+1,054
New +$648K 0.54% 47

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vahanian & Associates Financial Planning's REGN Position: Q2 2022 in Review

Vahanian & Associates Financial Planning sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 528 shares — an estimated $369K sold.

Vahanian & Associates Financial Planning first reported a position in REGN in Q4 2021 and held it in 2 quarters. The position peaked at $666K in Q4 2021. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • Vahanian & Associates Financial Planning reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Vahanian & Associates Financial Planning sold 528 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $369K.
  • Vahanian & Associates Financial Planning first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Vahanian & Associates Financial Planning's Regeneron Pharmaceuticals position peaked at $666K in Q4 2021.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Vahanian & Associates Financial Planning's 13F filing for Q2 2022, filed 27 Jul 2022.